Safety Strategy for Cephalon Pain Drugs Receives FDA Approval

According to a Cephalon news release, the FDA has approved a risk evaluation and mitigation strategy for Cephalon’s Fentora and Actiq drugs to manage breakthrough pain in opioid-tolerant patients with cancer.

Advertisement

Click here to read the Becker’s ASC Review coverage on Cephalon Fentora and Actig drugs.

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.